Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
News|Articles|May 12, 2025
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Advertisement
Advertisement
In some blood cancers, chimeric antigen receptor (CAR) T-cell therapy has been lifesaving. These treatments are engineered with patients’ own T cells to express a synthetic receptor, or CAR, that binds to antigens to set loose a powerful immune response. These treatments can destroy cancer or produce a prolonged response in pediatric leukemia, B-cell lymphoma, and multiple myeloma; for patients lacking options, CAR T can seem like a miracle.
Related to this article
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.
A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.
Advertisement
Advertisement